-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Nanjing Chia Tai Tianqing's anti-tumor fist product raltitrexed for injection was approved and passed the consistency evaluation
.
This product is an anti-metabolic drug among the anti-tumor drugs.
Figure 1: The latest approved products of Nanjing Chia Tai Tianqing
Source: CDE official website
Figure 2: Sales of raltitrexed for injection (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
Raltitrexed can specifically act on thymidylate synthase, thereby inhibiting cell DNA synthesis.
The metabolite form of its polyglutamate has a long half-life and can exert anti-tumor effects for a long time.
It is incomplete with fluorouracil.
Cross-resistance, mainly used to treat patients with advanced colorectal cancer who are not suitable for 5-Fu/leucovorin
.
According to data from Meinenet, in 2021H1, raltitrexed ranks seventh among the top 20 terminal antimetabolites in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions)
Currently in the domestic market, the original researched raltitrexed has not yet been approved for import.
Nanjing Chia Tai Tianqing declared and approved the first imitation application in China according to the original 3.
1 of the chemical drug in 2009.
In 2019, the sales in the terminal of public medical institutions in China exceeded 800 million yuan
.
In February 2021, Yangtze River's 3 types of imitations were approved for listing and deemed to have been reviewed.
Table 1: 2021H1 Nanjing Zhengda Tianqing TOP5 varieties
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
In 2021H1, at the terminal of public medical institutions in China, the five best-selling products of Nanjing Chia Tai Tianqing collectively contributed more than 60% of the company’s sales, of which raltitrexed contributed 11.
94%, which is the company’s role in the field of anti-tumor drugs.
Fist product
.
From the perspective of market competition, although the monopoly of the market has been broken, the reputation accumulated in the early stage is still active.
Source: CDE official website, Minet database
The review data statistics are as of October 18, if there are any errors or omissions, please correct me
